Literature DB >> 23329425

Comparing subsidized access to medicines across payer systems.

Michael Wonder, Richard Milne.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23329425     DOI： 10.1007/s40273-012-0010-9

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  6 in total

1.  Access to new medicines in New Zealand compared to Australia.

Authors:  Michael Wonder; Richard Milne
Journal:  N Z Med J       Date:  2011-11-25

2.  Patient access to new cancer drugs in the United States and Australia.

Authors:  Michael Wonder
Journal:  Value Health       Date:  2011-12-23       Impact factor: 5.725

3.  Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?

Authors:  Anne Mason; Michael Drummond; Scott Ramsey; Jonathan Campbell; Dennis Raisch
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

4.  Patient access to new cancer drugs in the United States and Australia.

Authors:  Andrew Wilson; Joshua Cohen
Journal:  Value Health       Date:  2011-07-29       Impact factor: 5.725

5.  Comparing patient access to pharmaceuticals in the UK and US.

Authors:  Joshua Cohen; Catherine Cairns; Cherie Paquette; Laura Faden
Journal:  Appl Health Econ Health Policy       Date:  2006       Impact factor: 2.561

6.  A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.

Authors:  Rajan Ragupathy; Katri Aaltonen; June Tordoff; Pauline Norris; David Reith
Journal:  Pharmacoeconomics       Date:  2012-11-01       Impact factor: 4.981
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.